1. Introduction {#s0005}
===============

Vascular dementia (VaD) is the second most common cause of age-related dementia after Alzheimer\'s disease (AD) [@bb0005]. Significantly extended life expectancy coupled with the sedentary lifestyle is predicted to increase the incidence of type 2 diabetes, hypertension and hyperlipidemia, all of which are risk factors for vascular disease and subsequent vascular cognitive impairment. The worldwide number of patients with vascular causes of dementia is expected to rise assuming no effective prevention strategies or curative treatments are developed and implemented [@bb0010].

Knowledge of VaD pathophysiology has been lagging behind AD for a number of reasons. The lack of suitable animal models and difficulties in obtaining well-characterized clinical samples has hampered the progress of basic and translational research on VaD. Immunohistochemical, neurochemical and electron microscopic studies using post-mortem clinical samples remained the mainstay of mechanistic research [@bb0015; @bb0020; @bb0025]. Neuroimaging together with clinical observation in patients has provided vital complementary information that forms the basis for the current understanding of VaD [@bb0030]. Multiple clinicopathologic substrates have been implicated in the pathogenesis (e.g. cortical or subcortical microinfarcts, demyelination of white matter, cribriform change of basal ganglia and white matter) that links cerebrovascular changes to cognitive impairment, independent of Alzheimer\'s type pathology [@bb0035]. However, the molecular events that drive these vascular and parenchymal changes in the brain are still poorly understood. Given the complexity and heterogeneity of cerebrovascular disorder and the presence of co-morbidities in VaD patients, it is likely that rather than an individual or small number of proteins, multiple candidate proteins present in networks are perturbed leading to the spectrum of cognitive and behavioral symptoms.

The advent of quantitative proteomic technologies using isobaric labeling strategy has made it possible to quantify several proteins in a single experiment for comparative study of global protein regulation across various biological samples. Isobaric tag for relative and absolute quantification (iTRAQ) is one of the most commonly used in vitro isotopic labeling strategies in different areas of biological science and medicine for simultaneously quantifying 4- or 8-plex samples [@bb0040]. Clinical proteomics of dementia have flourished in the recent times with a rapid increase in the number of studies analyzing different parts of the post-mortem brain of AD patients for expression profiling studies [@bb0045; @bb0050]. Apart from the well-known β-amyloid and tau hypothesis, the involvement of pathological events such as excitotoxicity, oxidative stress and inflammation has been highlighted. Post-translational modifications such as carbonylation and phosphorylation of various key proteins have also been found to contribute to AD.

Despite having immense potential to elucidate disease mechanisms, proteomic studies of VaD using preclinical or clinical samples are lacking. Recently, we have successfully applied an iTRAQ-based shotgun neuroproteomic strategy in the area of ischemic stroke to study validated pre-clinical models [@bb0055; @bb0060], and ischemic infarcts from autopsied human brain [@bb0065]. Here, we apply a similar iTRAQ-two dimensional-liquid chromatography--tandem mass spectrometry (iTRAQ-2D-LC--MS/MS) based quantitative proteomic approach on post-mortem VaD and matched non-demented control specimens from Brodmann area 21(BA21) of the temporal lobe for better understanding of the underlying molecular mechanism of VaD. We focused on the temporal lobe because medial temporal lobe atrophy is a common finding in dementia and our recent study suggested that there is a vascular basis for neurodegeneration [@bb0070]. The temporal lobe is also relatively free of large infarcts thus making it ideal to detect the survival response of the demented brain [@bb0075]. The iTRAQ experiment identified differentially expressed proteins from the pooled lysates of the two groups. Bioinformatics analysis of the proteomic data set revealed the aberrant regulation of proteins related to multiple cellular or subcellular events associated with VaD such as vascular dysfunction and oxidative stress. Some representative deregulated proteins were further validated by Western Blotting (WB) using individual patients. This study is the first quantitative proteomic investigation to reveal the differential global proteomes between VaD and age-matched control brain that provide a valuable data set for future basic or translational studies with individual proteins to propose potential therapeutic targets or biomarkers of VaD.

2. Materials and methods {#s0010}
========================

2.1. Reagents {#s0030}
-------------

Unless indicated, all reagents and assay kits were purchased from Sigma-Aldrich (St. Louis, MO, USA).

2.2. Patients and clinical assessments {#s0035}
--------------------------------------

We obtained frozen brain tissues from 10 non-demented elderly controls and 10 age-matched VaD subjects. The tissues were obtained from the Newcastle Brain Tissue Resource, Institute for Ageing and Health, Newcastle University. Demographic details of the subjects are summarized in [Table 1](#t0005){ref-type="table"} and can be found for individual subjects in the Supplemental Table 1. For this study, we assessed samples of the grey and white matter from BA21 area of the temporal lobe. VaD was clinically diagnosed using National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l\'Enseignement en Neurosciences criteria [@bb0080]. Pathological diagnosis of VaD was defined by the presence of multiple or cystic infarcts involving cortical and sub-cortical structures, border-zone infarcts, lacunae (\< 15 mm), micro-infarcts (visible by microscopy only) and small vessel disease in sub-cortical structures in the general absence of neurofibrillary tangles [@bb0075]. Clinical evidence of dementia along with the same type or a combination of these lesions at three different coronal levels was considered diagnostic for VaD. None of the VaD cases exhibited tangle burden diagnostic for AD or more than 'sparse' neuritic plaques as defined by Consortium to Establish a Registry for Alzheimer\'s Disease (CERAD) [@bb0085; @bb0090]. The cognitive assessments were made using Mini-Mental State Examination (MMSE) [@bb0095]. MMSE is a 30-point scale to evaluate the cognitive functions that cover orientation, memory, and attention. MMSE also includes the subject\'s ability to follow verbal and written commands. All control subjects were cognitively normal and they did not have any history of dementia, neurological disease or psychiatric conditions. The control participants did not qualify for the neuropathological diagnostic criteria of AD as none of the subjects had higher than Braak stage III/IV tangle burden or more than "sparse" plaque counts by CERAD criteria. Demographic and disease variables of the control and VaD patients indicated comparable samples for analysis ([Table 1](#t0005){ref-type="table"}; Supplemental Table 1).

Ethical approval was granted by local research ethics committees for this study (Newcastle upon Tyne Hospitals Trust, UK) and permission for post-mortem research using brain tissue was granted for this project. Additional approval for this study was obtained from the Institutional Review Board of the National University of Singapore. Informed consent was also obtained from the guardians of the patients prior to donation of brain tissues.

2.3. Experimental design {#s0040}
------------------------

The experimental design is described in [Fig. 1](#f0010){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}. Overall, it was divided into two phases, discovery phase and validation phase. The major challenge of expression profiling studies is to discriminate disease-specific changes from individual variations. To discover a consensus proteomic signature predictive of VaD and to gather enough amount of starting material, equal weight of tissues were pooled group-wise from 10 individual samples for the iTRAQ analysis in the discovery phase. Pooling has been suggested to get rid of the outliers or aberrant individual variations while highlighting most consistent disease-specific changes [@bb0100]. The tryptic digest from pooled control and VaD (n = 10 for each group) samples were labeled by two iTRAQ tags (114: control, 115: VaD) of the 4-plex iTRAQ kit. The iTRAQ experiment was repeated thrice (experimental replicate = 3, iTRAQ-1, iTRAQ-2, iTRAQ-3) using the pooled digest. Injection for LC--MS/MS was performed thrice (technical replicate = 3) for iTRAQ-1 and iTRAQ-2 and four times (technical replicate = 4) for iTRAQ-3 as multiple injections give better coverage of the target proteome with superior statistical consistency [@bb0105]. Thus, a total of 10 (= 3 + 3 + 4) MS injections were performed to generate ten individual data sets that will allow for the calculation of technical as well as experimental variations arising from individual iTRAQ experiments. Post-proteomic validation of selected proteins from the iTRAQ data set was performed on individual patients (biological replicate = 10 for control and VaD group) using a separate tissue specimen from the BA21 area of the same individual by WB analysis to measure the extent of biological variation.

2.4. Proteomics {#s0045}
---------------

### 2.4.1. Sample preparation {#s0050}

Sample processing including centrifugation and sonication were performed at 4 °C unless mentioned otherwise. A biphasic chloroform/methanol extraction coupled with acetone precipitation was adopted with slight modifications as described previously [@bb0110; @bb0115]. This is to maximize the recovery of various macromolecules and matabolites from scarce clinical specimens suitable for downstream processing through different -omics platforms. Briefly, equal quantities of frozen tissues (w/w) were pooled in a group-wise manner and grounded into fine powder using liquid nitrogen before being suspended in a mixture of methanol (Merck KGaA, Darmstadt, Germany), chloroform and water (J.T. Baker, Center Valley, PA, USA) (1:1:2). The suspension was mixed for 1 h and subsequently centrifuged (15 000 ×*g*, 2 min) to obtain the pellet. The non-polar chloroform fractions were kept for separate studies. The previous step was repeated using a mixture of methanol, chloroform and water (4:1:3) for washing the pellet. The polar methanol--water phase was combined from consecutive steps and mixed with acetone (overnight, 4 volumes of acetone, − 20 °C) followed by centrifugation (15 000 ×*g*, 5 min) to precipitate the residual proteins. Methanol was used subsequently to wash the protein containing pellets and remove contaminants that were followed by centrifugation (15 000 ×*g*, 2 min). Protein pellets were dissolved in 8 M urea with protease inhibitor cocktail (Complete (Roche; Mannheim, Germany)) by intermittent sonication for 20 s (amplitude, 30%) using a Vibra Cell high intensity ultrasonic processor (Jencon Scientific Ltd.; Leighton Buzzard, Bedfordshire, U.K.). It was subsequently centrifuged (20 000 ×*g* for 30 min) to collect the supernatant. The protein concentration of the supernatant was determined by the bicinchoninic acid assay.

### 2.4.2. In-gel tryptic digestion and isobaric labeling {#s0055}

The samples (250 μg of proteins/condition) were then reduced (5 mM tris-(2-carboxyethyl) phosphine, 30 °C, 3 h) and alkylated (20 mM methyl methanethiosulfonate in isopropanol, room temperature, 45 min in dark) followed by a two-step digestion (16 h + 4 h) at 30 °C with sequencing-grade modified trypsin (Promega, Madison, WI, USA) at a ratio of 1:100 (trypsin: sample) in 50 mM triethylammonium bicarbonate (TEAB). The tryptic digested peptides were desalted using Sep-Pak C18 cartridges (Waters, Milford, MA, USA) and dried in a vacuum centrifuge. The dried peptides were reconstituted into 0.5 M TEAB and labeled with respective isobaric tags of 4-plex iTRAQ reagents (Applied Biosystems, Foster City, CA, USA) as follows: control, 114; VaD, 115 ([Fig. 1](#f0010){ref-type="fig"}). The labeled peptides were combined and dried in a vacuum centrifuge. The iTRAQ sample was desalted using Sep-Pak C18 cartridges and dried before fractionation. Three batches of experimental replicates were prepared separately as showed in the experimental design.

### 2.4.3. Electrostatic repulsion and hydrophilic interaction chromatography (ERLIC) {#s0060}

The mixture of iTRAQ-labeled peptides was fractionated using a PolyWAX LP anion-exchange column (4.6 × 200 mm, 5 μm, 300 Å) (PolyLC, Columbia, MD, USA) on a Prominence UFLC system (Shimadzu, Kyoto, Japan) and monitored at the wavelength of 280 nm. Thirty five fractions were collected during a 60 min gradient of 100% buffer A (0.1% acetic acid, and 10 mM ammonium acetate in 85% acetonitrile (ACN)) for 5 min, 0--36% of buffer B (0.1% formic acid (FA) in 30% ACN) for 25 min, 36--100% of buffer B for 20 min, and 100% of buffer B for the last 10 min at a flow rate of 1 ml/min [@bb0120; @bb0125]. Eluted fractions were pooled into 26 fractions depending on the peak intensities. They were dried in a vacuum centrifuge and redissolved in 0.1% FA in 3% ACN for LC--MS/MS analysis.

### 2.4.4. Reverse phase LC--MS/MS analysis using QSTAR {#s0065}

Each fraction of redissolved iTRAQ-labeled peptides was sequentially injected in triplicate and separated in a home-packed nanobore C18 column with a picofrit nanospray tip (75 μm ID × 15 cm, 5 μm particles) (New Objectives, Woburn, MA, USA) on a Tempo nano-MDLC system coupled with a QSTAR Elite Hybrid MS (Applied Biosystems/MDS-SCIEX). Each fraction was independently analyzed by the LC--MS/MS over a gradient of 90 min with the constant flow rate of 300 nl/min. Data acquisition in QSTAR Elite was set to positive ion mode using Analyst QS 2.0 software (Applied Biosystems). The precursors with a mass range of 300--1600 m/z and calculated charge from + 2 to + 5 were selected for fragmentation. For each MS spectrum, 5 most abundant peptides at most above a 5-count threshold were selected for MS/MS, and the selected precursor was dynamically excluded for 20s with a mass tolerance of 0.1 Da. Smart information-dependent acquisition was activated with automatic collision energy and automatic MS/MS accumulation. The fragment intensity multiplier was set to 20 and maximum accumulation time was 2 s.

### 2.4.5. Mass spectrometric raw data analysis {#s0070}

Spectra acquired from each of the technical and experimental replicates were submitted alone and together to ProteinPilot Software (v 3.0, Revision Number: 114 732, Applied Biosystems) for peak list generation, protein identification and quantification against the concatenated target-decoy Uniport human database (downloaded on 12 March 2012). User defined parameters in ProteinPilot software were configured as described previously [@bb0055] with minor modifications as follows: (i) Special factors, urea denaturation; (ii) Specify Processing, quantitate, bias and background correction. Default precursor and MS/MS tolerance for QSTAR ESI-MS instrument were adopted automatically by the software. The false discovery rates (FDR) of both peptide and protein identification were set to be less than 1% (FDR = 2.0 ∗ decoy_hits / total_hits).

### 2.4.6. Bioinformatics analysis {#s0075}

The open-source software Panther and David were used for the enrichment analysis in various categories like Gene Ontology and pathways by submitting Uniprot accession numbers of the short-listed proteins [@bb0130; @bb0135]. The human proteome was used as a default background for David. The enrichment analysis in David identifies overrepresentation of certain phenotype (i.e. a group of proteins common to a specific pathway, class, location, function, disease or any other attribute) from long list of regulated proteins that did not occur only by chance. Significances were expressed by fold of enrichment and *p*-value before and after corrections with Benjamini--Hochberg or modified Fisher\'s exact test. Any phenotype was considered enriched when the *p*-value was less than 0.01 and FDR less than 1% after corrections with both the above-mentioned methods.

### 2.4.7. Post-proteomic validation {#s0080}

#### 2.4.7.1. Sample processing {#s0085}

The samples were briefly thawed on ice and dissected to remove meninges and exclude the blood vessels and the white matter. Cleaned samples were then homogenized at 50 mg tissue/ml in an ice cold cell lysis buffer (20 mM Tris--HCl, 150 mM NaCl, pH 7.5) (Cell Signaling Technology, Danvers, MA, USA). Protease inhibitor cocktail (Complete (Roche)) was added immediately before use. Protein concentrations were measured using a 2-D Quant kit (Amersham Biosciences, Piscataway, NJ, USA).

#### 2.4.7.2. WB analysis {#s0090}

WB was performed after SDS-PAGE by probing with primary antibodies at the indicated dilutions: anti-ACTB (beta-actin, 1:10 000, mouse monoclonal; Millipore, Billerica, MA, USA), anti-BCL2 (B-cell CLL/lymphoma 2, 1:1000, mouse monoclonal; Santa Cruz Biotech, Santa Cruz, CA, USA), anti-ferritin (1:4000, rabbit polyclonal; Abcam, Cambridge, UK), anti-HSPA4 (heat shock 70 kDa protein 4, 1:5000, mouse monoclonal; Abcam), anti-ICAM5 (intercellular adhesion molecule 5, 1:1000, rabbit polyclonal; Abcam), anti-NCAM (neural cell adhesion molecule, 1:10 000, rabbit polyclonal; Santa Cruz Biotech), anti-PEA15 (phosphoprotein enriched in astrocytes, 1:800, rabbit polyclonal; Abcam), anti-SOD1 (superoxide dismutase 1, 1:2000, rabbit polyclonal; Abcam), anti-syntaxin (1:10 000, mouse monoclonal; Milipore), anti-SYNPO (synaptopodin, 1:1000, rabbit polyclonal; Abcam) and anti-VDAC1 (voltage-dependent anion channel 1, 1:5000, mouse monoclonal; Santa Cruz Biotech). Immunoblotting of ACTB was used as a loading control. Apart from that, two commercially available antibody cocktails were used; Mitoprofile Total OXPHOS Human WB Antibody Cocktail (1:2000, mouse monoclonal, MS601; Mitoscience, Eugene, Oregon) and Apoptosis Western Blot Cocktail (1:250, MS1107; Mitoscience). MS601 consisted of five antibodies targeting key proteins of oxidative phosphorylation (i.e. NADH dehydrogenase \[ubiquinone\] 1 beta subcomplex subunit 8, mitochondrial (NDUFB8); Cytochrome c oxidase subunit 2 (MT-CO2), Succinate dehydrogenase \[ubiquinone\] iron--sulfur subunit, mitochondrial (SDHB); Cytochrome b-c1 complex subunit 2, mitochondrial (UQCRC2) and ATP synthase subunit alpha, mitochondrial (ATP5A)). MS1107 detects 32 kDa pro-caspase 3, 17 kDa active caspase 3, 89 kDa apoptosis-specific cleaved Poly \[ADP-ribose\] polymerase 1 (PARP) along with muscle actin which is incorporated as a loading control. This cocktail does not react with full-length PARP. Twenty to forty micrograms of proteins were used for WB depending on the sensitivity of the specific antibody. Immunoreactivity was detected by using an HRP chemiluminescent substrate reagent kit (Invitrogen, Carlsbad, CA). A pooled sample was used to normalize the inter-gel variation between repeated runs for the same protein.

#### 2.4.7.3. Statistical analysis {#s0095}

All statistical analyses were performed using SPSS 13.0 for Windows software (SPSS Inc.). Normality of data was first checked using the Kolmogorov--Smirnov test. Independent sample *t*-test was used to compare the means of control and VaD group. Equal variances were assumed for the calculation of *p*-values as the two groups had equal number of subjects (n = 10). Non-parametric Mann--Whitney *U* Test was used for comparing non-normal distributions. Correlations involving only continuous data (i.e. age, post-mortem interval, and protein abundance) were analyzed by Pearson\'s product moment correlation. Spearman\'s rank correlation was used when one of the variables are ordinal in nature (i.e. MMSE score, Braak staging, and CERAD score). Experimental data for WB analysis were presented as mean ± SEM. Statistical significance was accepted at \**p* \< 0.05 and \*\**p* \< 0.01.

3. Results {#s0015}
==========

To understand the global proteomic change in VaD, pooled tissue extracts were compared between groups of age-matched control and VaD subjects by iTRAQ experiment.

3.1. Quality control of iTRAQ data set {#s0100}
--------------------------------------

A strict cut-off of unused ProtScore ≥ 2 was used as the qualification criteria to minimize the false positive identification of proteins. With this criteria, 1569, 2039 and 1525 proteins were identified from the three iTRAQ experiments with a FDR of \< 0.8%. To improve the confidence of identification and quantification, all ten individual injections from the three iTRAQ experiments were combined for subsequent analysis. The combined data set had 2281 proteins with a FDR of 0.3% using the ProtScore cut-off mentioned above (Supplemental Table 2). The average number of unique peptides (having a confidence level of ≥ 95%) detected per protein was 21.8. More than 55% of the proteins (1260 proteins) had ≥ 5 unique peptides, while around 14% of proteins were identified with a single peptide. The average % coverage for the combined data set was 28.2%, whereas around 39.4% of the proteins (901 proteins) had % coverage more than the average level. Intriguingly, some proteins were identified with 100% sequence coverage (e.g. Hemoglobin subunit beta (HBB), Gamma-synuclein, and Fructose-bisphosphate aldolase C) (Supplemental Table 2). This result is better than our previously published report where a single iTRAQ experiment was performed to study the regulated proteome [@bb0060]. To the best of our knowledge, this data set is likely the biggest neuroproteomics data set from similar iTRAQ based quantitative clinical proteomic study. Next, the ratios were sorted using a *p*-value cut-off of 0.05 to shortlist a set of 171 significantly perturbed proteins for further analysis.

3.2. Estimation of threshold for confidently defining perturbed proteins {#s0105}
------------------------------------------------------------------------

To determine the cut-off for up- or down-regulation, the deviation of ratios (i.e. 115/114) of individual proteins between various technical and experimental replicates were measured as described previously [@bb0055; @bb0060]. The proteins that have been confidently identified in at least 3 injections were included. Accordingly, geometric mean, standard deviation and %coefficient of variation (%CV) of 1878 proteins were determined. The average %CV was around 13%. The %CV was less than 20% and 40% for more than 84% and 98% of the proteins ([Fig. 2](#f0015){ref-type="fig"}). Based on this, the regulation threshold was set at 1.4 fold; ratio \> 1.40 or \< 0.71 was considered as up- or down-regulated respectively. Applying this threshold to the 171 significantly perturbed proteins, a list of 144 proteins (6.3% of initial hits) was obtained; where 72 each were up- and down-regulated (Supplemental Table 3). This was advanced to the next stage for bioinformatics analysis to retrieve hidden biological trends.

3.3. Bioinformatics analysis {#s0110}
----------------------------

Bioinformatics analysis revealed up-regulation of various neurotransmitter signaling pathways (e.g. glutamate and acetylcholine) while glycolysis, tricarboxylic acid cycle, ATP synthesis and pyruvate metabolism were featured among the down-regulated pathways. Recently, the up-regulation of GluR2 subunit of glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor was reported in the BA22 area of the VaD brain when compared with age-matched control and mixed AD/VaD cases, which is concordant with the trends observed in our study [@bb0140]. Proteins related to metabolic, immune system process, cell adhesion and apoptosis exhibited mixed trends. Majority of metabolic proteins (77.9%, 60/77) were decreased in the VaD brain, while proteins linked to cell adhesion (90.9%, 10/11) and immune system processes (61.1%, 11/18) were elevated. This is consistent with a recent RNA microarray study reporting the up-regulation of genes associated with cell adhesion and immune response in the deep subcortical white matter lesion [@bb0145]. The levels of most of the perturbed extracellular proteins (87.5%, 7/8) including FGB, COL6A3, NCDN, VCAN, and NFASC were increased. Among the perturbed protein classes, the calcium binding proteins (80%, 4/5; SLC25A3, SPTBN2, SPTBN1, PLEC) and chaperones (71.4%, 5/7; HSPB1, HSPA5, STIP1, CCT8, TBCA) were mainly elevated while all proteases (5/5; e.g. NPEPPS, PREP and PSMA6) were reduced in the VaD brain. Finally, guided by the above trends, the selected list of proteins was manually classified into various functional categories with additional proteins taken from the complete data set based on their relevance with the respective categories ([Table 2](#t0010){ref-type="table"}).

3.4. Post-proteomic validation by WB analysis {#s0115}
---------------------------------------------

Eleven proteins (i.e. SOD1, NCAM, ATP5A, UQCRC2, SYNPO, HSPA4, VDAC1, ferritin, PEA15, ICAM5 and syntaxin) were selected from the list of 171 significantly regulated proteins for validation in twenty subjects individually ([Fig. 3](#f0020){ref-type="fig"}). They were selected from a wide range of molecular functions according to the bioinformatics analysis, such as energy metabolism (e.g. ATP5A, UQCRC2), oxidative stress (e.g. SOD1, ferritin),inflammation (e.g. NCAM, ICAM5), synaptic transmission (e.g. SYNPO, syntaxin) and apoptosis (e.g. HSPA4, PEA15, VDAC1). In addition, three more candidates (i.e. SDHB, MT-CO2 and NDUFB8) related to oxidative phosphorylation were also included as negative control to check the reliability of the relative quantization as none of them were significantly (*p* \> 0.05) regulated in the proteomics result ([Table 2](#t0010){ref-type="table"}). It should be noted here that unlike iTRAQ experiment, which was performed on pooled lysates, the *p*-value in the WB analysis is an estimate of the biological variation based on the cohort of twenty individuals.

The abundance of SOD1 (*p* = 0.014) and NCAM (*p* = 0.018) was significantly higher whereas ATP5A (*p* = 0.047) and UQCRC2 (*p* = 0.006) were significantly lower in VaD compared to the controls. SYNPO (*p* = 0.062), HSPA4 (*p* = 0.100) and VDAC1 (*p* = 0.168) showed a decreasing trend unlike ferritin (*p* = 0.192), PEA15 (*p* = 0.114) and ICAM5 (*p* = 0.578) that showed an increasing trend in the VaD group. A poor *p*-value for WB analysis is related to higher individual variation in the expression of a protein within the same group. Hence, increasing the number of subjects per group could have resulted in a statistically significant difference for some of the above mentioned candidates. Considering the groups were not gender-matched, individual abundances of all proteins from WB results were compared between male (n = 9) and female (n = 11) to evaluate the influence of gender as a potential confounding factor. The levels of UQCRC2 were found to be significantly lower (*p* = 0.027) in male compared to female subjects thus excluding it from further discussion.

Syntaxin did not exhibit any difference between VaD and control groups by WB, although it was found to be up-regulated (i.e. STX1A and STX1B, \~ 1.8 fold) in the iTRAQ analysis ([Table 2](#t0010){ref-type="table"}). This ambiguity can be related to the sampling of an independent piece of tissue for proteomic and WB validation experiment or may have arisen from the different sample processing protocols. The three negative controls (SDHB, MT-CO2 and NDUFB8) did not show difference between VaD and control brain tissues in both WB and iTRAQ, indicating the reliability of the sample pooling strategy in the discovery phase. Overall, a consistent trend was observed with the iTRAQ result for the selected proteins with the exception of syntaxin.

3.5. Correlation analyses {#s0120}
-------------------------

One of the major confounding factors for studies involving post-mortem specimens of geriatric subjects is sampling artifact that may alter pattern or magnitude of protein expression [@bb0150]. Correlation analysis was performed for two groups of subjects individually and in combination in order to study linear associations between the immunoreactivities of the key perturbed proteins and available neuropathological or clinical variables. Individual abundances of none of the proteins used for WB validation correlated with age or post-mortem interval of the recruited subjects thereby excluding the presence of systematic bias related to the sample collection. Moderate to strong correlations were obtained in between the abundances of various proteins selected for validation. Notably, immunoreactivities of two significantly elevated proteins in the VaD brain (i.e. SOD1 and NCAM) were positively correlated with various mitochondrial proteins such as VDAC1 (SOD1, r = 0.86, *p* \< 0.01), SDHB (SOD1, r = 0.76, *p* \< 0.05; NCAM, r = 0.65, *p* \< 0.05), and MT-CO2 (SOD1, r = 0.71, *p* \< 0.05; NCAM, r = 0.80, *p* \< 0.01) and were negatively correlated with the synaptic protein, syntaxin (SOD1, r = − 0.77, *p* \< 0.05; NCAM, r = − 0.69, *p* \< 0.05). No association was found between the protein levels and MMSE scores for the VaD group. Detailed results of the correlation analysis can be found in the Supplemental Table 4.

4. Discussion {#s0020}
=============

To our knowledge, this is the first comparative proteomic profiling of post-mortem brain tissues of VaD and control subjects by combining the attributes of biphasic chloroform/methanol extraction for sample preparation, multiplex isobaric labeling with iTRAQ reagent chemistry, two dimensional liquid chromatography, nano-electrospray ionization and high resolution tandem mass spectrometry (iTRAQ-2D-LC--MS/MS).

4.1. Unraveling the pathophysiology of VaD --- a systems biological perspective {#s0125}
-------------------------------------------------------------------------------

To ensure specificity of dementia due to vascular causes and not due to the presence of co-morbidities, extensive neuropathological characterization was performed to exclude confounding from two other possible causes of dementia (e.g. AD and dementia with Lewy bodies (DLB)). VaD samples did not exhibit significant Alzheimer\'s type of pathology as the neuritic plaques were confined to only the entorhinal areas (stage I--II) ([Table 1](#t0005){ref-type="table"}). These stages are generally considered to be without symptoms or be associated with little evidence of dementia [@bb0155]. Additionally, immunoreactivity of none of the tested fourteen candidates\' correlated with the Braak staging (n = 17), MMSE score (n = 7) and CERAD score (n = 10) thus excluding probable etiological association between key perturbed proteins with Alzheimer\'s pathology (Supplemental Table 4). Neuropathological examination also confirmed the absence of Lewy body pathology in the selected subjects (data not shown). Hence, the presence of cognitive impairment as seen by the low MMSE scores in the VaD group ([Table 1](#t0005){ref-type="table"}) was associated with cerebrovascular pathology through the deregulation of different functional classes of proteins found in the current data set.

4.2. Cortical hypoperfusion and vascular dysfunction in VaD {#s0130}
-----------------------------------------------------------

The plasma proteins in our short-listed data set may allow better understanding of the perfusion status of the brain in VaD subjects. The significantly up-regulated list of proteins in the proteomic data set was dominated by different isoforms of immunoglobins (e.g. IGHA1, IGHG2, IGSF8, IGLC2 and IGKC) and other known plasma proteins (e.g. FGB). Intriguingly, HBB was the protein with maximum fold of down-regulation. HBD also showed significant down-regulation albeit with lesser magnitudes ([Table 2](#t0010){ref-type="table"}, [Fig. 4](#f0025){ref-type="fig"}). Hemoglobins (i.e. HBB and HBD) generally remained entrapped in the erythrocytes, which does not extravasate beyond the circulation unless there is a hemorrhage. The decreased presence of hemoglobin may be indicative of a perfusion failure in the VaD cortex along with a diffuse leakage of the blood brain barrier (BBB) that is manifested by an apparent increase in the levels of several proteins of circulatory source. In addition, we observed significant down-regulation of a key component of oxidative phosphorylation (i.e. ATP5A) while HSPA4 and mitochondrial protein VDAC1 showed down-ward trends during WB validation indicating a state of hypometabolism and mitochondrial failure ([Fig. 3](#f0020){ref-type="fig"}). Further, the up-regulation of an isoform of collagen (i.e. COL6A3) in the iTRAQ result may indicate accumulation of extracellular matrix components that could cause collagenosis and vascular stenosis thus aggravating the perfusion failure [@bb0160]. The unraveled molecular events from our unbiased quantitative proteomic study may offer a mechanistic explanation for previous observations from neuroimaging and neuropathologic studies. The disruption of BBB in small vessel disease has been documented using dynamic contrast-enhanced magnetic resonance imaging in live patients and through immunohistochemistry of immunoglobulins and fibrinogen of brain tissue [@bb0165; @bb0170]. Cortical hypometabolism and hypoperfusion have been detected with functional imaging like positron emission tomography in patients of VaD in comparison with healthy controls [@bb0175] and by two-dimensional xenon-133 inhalation technique in the ipsilateral fronto-parietal cortex in the presence of sub-cortical infarcts [@bb0180].

Considering chronic leakage of fluid and macromolecules, a likely consequence will be induction of an inflammatory response in the temporal cortex of VaD brain. Subsequently, curating the proteomic data set for other hallmarks of inflammation identified few adhesion molecules (e.g. L1CAM, NCAM1, ICAM5) showing an up-regulation in the VaD group ([Table 2](#t0010){ref-type="table"}, [Figs. 3](#f0020){ref-type="fig"}, 4). The decrease in HSPA4, which normally functions as a chaperone and protects cells from inflammation during cerebral ischemic injury, may further worsen the inflammatory condition [@bb0185]. The levels of L1CAM and NCAM were found to be higher in the cerebrospinal fluid (CSF) of VaD, AD and MIX dementia patients compared to non-demented controls [@bb0190]. Soluble form of ICAM5 has been detected in the serum within the first 48 h of cerebral hypoxic--ischemic injury of mice, where shredded neuronal ICAM5 could act as an anti-inflammatory agent by suppressing the T-cell activation [@bb0195; @bb0200].

4.3. Deregulation of iron metabolism and oxidative stress {#s0135}
---------------------------------------------------------

In the human brain, iron is ubiquitous and is responsible for the activity of key enzymes (e.g. cytochromes, mitochondrial non-haem iron proteins) and for the synthesis of neurotransmitters. Most of the total iron in a healthy brain is sequestered by ferritin thus limiting its pro-oxidant potential. Brain ferritin-associated iron levels increase with age. Abnormal elevation of brain iron and ferritin has been reported in the neurodegenerative dementias (i.e. AD, PD and dementia with Lewy Bodies) suggesting that increased iron levels may contribute to the misfolding and subsequent deposition of key proteins [@bb0205]. Although consistent correlation between iron accumulation and cognitive dysfunction has been documented in animal or clinical studies related to neurodegenerative diseases like AD, similar reports are scarce in the area of VaD [@bb0210]. Here, we report an increase of brain ferritin (H- and L-isoforms) levels of VaD patients compared to the age-matched control group ([Table 2](#t0010){ref-type="table"}, [Fig. 3](#f0020){ref-type="fig"}). Interestingly, out of the tested fourteen candidates for validation, only the levels of ferritin (r = 0.76, *p* \< 0.05) positively correlated with the duration of illness in the VaD group (n = 8) indicating a probable increase in iron accumulation along with the progression of VaD (Supplemental Table 4).

Considering that increased level of ferritin may help the demented brain to adapt against the oxidative stress by capturing the free iron, the significant up-regulation of SOD1 in VaD brain could have a complementary protective role. SOD1 catalyzes the dismutation of superoxide anion (O~2~^−^) into oxygen and hydrogen peroxide (H~2~O~2~). The O~2~^−^ can react with ferric iron (Fe^3 +^) by Haber--Weiss reaction to produce ferrous iron (Fe^2 +^) which further reacts with H~2~O~2~ by Fenton reaction to generate highly reactive and damaging hydroxyl radical (OH^−^) ([Fig. 5](#f0030){ref-type="fig"}). Hence, both ferritin and SOD1 could work in tandem to remove ferrous iron (Fe^2 +^) and O~2~^−^ radicals thereby preventing oxidative injury in the demented brain. Nevertheless, we also observed an upward trend for GPX in the proteomic data set, an enzyme that reduces H~2~O~2~ to water using reduced glutathione (GSH). Several studies with animal models of ischemic stroke (focal or global cerebral ischemia) have demonstrated the neuroprotective potential of SOD1 [@bb0215]. In line with that, we have seen reduced levels of SOD1 and elevated levels of ferritin in the ischemic infarcts (i.e. core of injury), when compared with matched control subjects [@bb0065]. Recently, SOD1 has been selected to genetically modify neural stem cells as its overexpression has improved their survival following intracerebral administration in rodent models of ischemic stroke. This is consistent with the probable protective role of SOD1 as discussed above [@bb0220].

4.4. Mechanisms of cell death in VaD {#s0140}
------------------------------------

Inflammatory and oxidative stress mechanisms as discussed above are suggested to precede apoptosis that finally causes cell death in the demented brain [@bb0035; @bb0145]. Recent studies have demonstrated neuronal apoptosis as one of the contributing pathways of cell death in the neocortex of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy [@bb0225]. Hence, to elucidate the pathways that seal the fate of the stressed cells in this group of VaD patients, we had tested the expression of well-known apoptotic markers that include pro-caspase 3, p17 subunit of active caspase 3, cleaved PARP along with anti-apoptotic BCL2 protein. Pro-caspase 3 forms activated caspase 3 at the initiation of apoptotic cascade that proteolytically cleaves the DNA repair enzyme, PARP to generate the 89 kDa apoptosis-specific PARP fragment. However, no significant differential expression of pro-caspase-3 and BCL2 between VaD and control subjects was observed ([Fig. 6](#f0035){ref-type="fig"}). The PARP fragment and p17 subunit of caspase 3 remained undetected in either group following WB analysis indicating the absence of significant degradation of the PARP enzyme by active caspase 3. Therefore, our data points toward the involvement of non-apoptotic pathways of cell death in the cortex of the studied VaD patients. However, there is tantalizingly little data on the underlying mechanisms of cell death in VaD and the participation of autophagy has been speculated [@bb0035].

Overall, our quantitative proteomic approach documents the up-regulation of seemingly protective and deleterious pathways simultaneously in the temporal cortex of the VaD subjects. An inflammatory condition (i.e. NCAM1) or vascular insufficiency (e.g. HBB) and a decline in the energy metabolism (i.e. ATP5A1) are accompanied by the up-ward trend for anti-inflammatory (i.e. ICAM5), anti-apoptotic protein (i.e. PEA15) or proteins related to iron storage (i.e. FTL, FTH1) or anti-oxidative function (i.e. SOD1) ([Fig. 4](#f0025){ref-type="fig"}). This penumbra-like condition is not surprising considering the presence of predominant sub-cortical lesions in these VaD subjects as we deliberately sampled one neocortical area (i.e. BA21) that is located at a distance from the epicenter of the vascular injury. Accordingly, the synaptic proteins (e.g. syntaxin) did not show a unanimous reduced expression indicating no generalized synaptic decline as seen in the case of AD affected brain [@bb0025]. Hence, our proteomic result was able to identify the key molecular substrates behind different pathological processes that work in concert to cause the demise of the brain cells in VaD. Further studies on larger cohort of patients and with pre-clinical models could better explain these aberrant regulations and their interactions with the existing supportive therapies of VaD like cholinesterase inhibitors, antioxidants or vasodilators.

5. Limitations {#s0145}
==============

Being a study performed using PM specimens; the data interpretation is limited by the availability of samples. The groups were not matched by sex and gender was found to be a confounding factor for one of the candidate proteins (i.e. UQCRC2) shortlisted for WB validation. However, all other proteins including pro-caspase-3 and BCL2 did not show significant difference between male and female groups. The age of onset of VaD is variable among individuals along with their different lifestyle and genetic backgrounds. Details of co-morbidities, risk factors, medications and exact cause of death are not available. Despite these limitations, they had similar clinical and neuropathological presentations in a group-wise manner that made the proteomic comparison of pooled samples of identical brain location possible.

Our experimental design did not include groups of subjects with clinically or biochemically overlapping pathologies such as AD, DLB or ischemic stroke for a comparative validation of the short-listed candidates. Hence, our conclusions are necessarily limited to VaD as we are unable to comment on the specificity of the reported candidates in the context of other dementias or degenerative diseases. It would be worthwhile to follow up the current work with samples from other types of dementia to address the question of individual protein\'s specificity to the pathology of interest.

Although confident identification of around 10% of human proteome indicates the analytical sensitivity of the current experimental design, cellular or subcellular localization and distribution of the regulated proteins among different cell-types are not clear from our experiment. We tried to partially address this by selecting relatively cell-type specific candidates (e.g. PEA15, SYNPO, syntaxin) for data interpretation and validation. Immunohistochemical studies on similar samples targeting some of the regulated candidates will be complementary to this approach.

6. Conclusions {#s0025}
==============

Our quantitative clinical proteomic study demonstrates deregulated proteome of the temporal cortex of VaD patients compared to non-demented control subjects. We have successfully applied novel sample preparation methods compatible with the systems approach to confidently identify 2281 proteins by iTRAQ experiment using a group-wise sample pooling strategy. The majority of the deregulated proteome has never been reported in context of VaD or dementia. In addition, we were able to obtain statistically significant difference of three candidate proteins (SOD1, NCAM and ATP5A) between VaD and control brain based on the WB analysis of twenty individual subjects. Some of the key proteins that play crucial roles in the progressive parenchymal and vascular changes during VaD, like cortical hypoperfusion, hypometabolism, inflammation and oxidative stress were identified in a single experiment. The parallel aberrant regulation of multiple proteins may indicate an early degenerative changes or an actively ongoing adaptive process that can only be captured by a systems biological tool like proteomics. The tissue samples represent the most proximal source to determine the pathologic alteration of proteome that could eventually be reflected in the CSF or plasma. Thus, the up-regulated proteome could provide a list of potential candidates for future exploration of biomarkers from body fluids by targeted analysis in clinically similar cohorts of VaD patients. Detailed understanding of these pathologic events and their correlation with dementia and cerebrovascular pathology through follow-up studies could provide potential therapeutic targets for VaD.
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![Schematic representation of experimental design showing discovery and validation phase.](gr1){#f0010}

![Percent variation in iTRAQ ratios (115/114) between the same protein found in various technical and experimental replicates following MS. The primary vertical axis represents the corresponding number of the proteins (bars) having different % co-efficient of variation (%CV) that was plotted in the horizontal axis. The secondary vertical axis represents the cumulative % of the counted proteins (lines) where 100% equals to 1878 proteins. These proteins have confidently been identified in at least 3 out of 10 MS runs. Ninety eight percent of the proteins had less than 40% of %CV. Accordingly; the regulation cut-off was set at 1.4-fold.](gr2){#f0015}

![Post-proteomic validation of the selected proteins using individual patients from control and VaD groups by WB analysis. Equal amount of protein was loaded as measured by the 2D Quant kit. A) Representative immunoblots showing the protein levels in B21 area of all twenty patients (n = 10 per group). Details of the patients can be found in the Supplemental Table 1. ACTB was used as a loading control. B) Bar chart of densitometric analysis for comparing the protein expression levels by the statistical analysis. SOD1 and NCAM were significantly increased whereas ATP5A was reduced significantly in the VaD brain. Trends were observed for SYNPO, HSPA4, VADC1, ferritin, PEA15 and ICAM5 without reaching a statistical significance. Data was presented as mean ± SEM (n = 10), where \**p* \< 0.05, significantly different from control using independent-sample *t*-test.](gr3){#f0020}

![Schematic diagram showing the interplay of various vascular and parenchymal events during the evolution of VaD. ↑, up-regulation; ↓, down-regulation.](gr4){#f0025}

![Schematic diagram showing the probable involvement of SOD1 and ferritin (FTL, FTH1) in detoxifying the demented brain cells from iron overload and oxidative imbalance.](gr5){#f0030}

![A. Representative immunoblots showing the levels of important markers of apoptosis in the temporal cortex of control and VaD patients. B. Bar chart of band densities (in arbitrary units) involving all twenty individuals and normalized with the expression of muscle actin, which was used as a loading control. There were no statistically significant difference in the abundance of BCL2 and pro-caspase 3 between control and VaD group. Data was presented as mean ± SEM (n = 10), where \**p* \< 0.05, significantly different from control using independent-sample *t*-test.](gr6){#f0035}

###### 

Demographics and disease variables for groups of control and VaD patients.

  Demographics                                                                               Control       VaD
  ------------------- ---------------------------------------------------------------------- ------------- ---------------
                      Number of cases                                                        10            10
                      Age at death (mean yrs ± SD)[a](#tf0005){ref-type="table-fn"}          80.3 ± 8.9    84.0 ± 8.5
                      Sex (male/female)                                                      2 M/8 F       7 M/3 F
                      Duration of illness (yrs)                                              na            3.8 ± 3.5
                      Post-mortem interval (median ± IQR)[a](#tf0005){ref-type="table-fn"}   24.5 ± 24.0   36.5 ± 41.0
  Disease variables                                                                                        
                      Pre-death MMSE (median ± SD/N)                                         na            14.3 ± 3.7(6)
  Braak staging (N)   0--II                                                                  5             9
                      III--IV                                                                3             0
                      V--VI                                                                  0             0
                      NA\*                                                                   2             1

SD, standard deviation; IQR, interquartile range. na, not applicable; \*NA, Not available.

The groups were not significantly different in terms of Age (independent sample *t*-test, *p*-value \> 0.05) or post-mortem interval (Mann--Whitney *U* test, *p*-value \> 0.05).

###### 

Significantly regulated proteome of VaD selected from the complete list of confidently identified proteins[a](#tf0010){ref-type="table-fn"}.

  N                                           Unused   %Cov (95)   Gene symbol   Name                                                                                                            Peptides (95%)   VaD: Control (115:114)   EF^†^ (115:114)
  ------------------------------------------- -------- ----------- ------------- --------------------------------------------------------------------------------------------------------------- ---------------- ------------------------ -----------------
  **Energy metabolism**                                                                                                                                                                                                                    
  Glycolysis                                                                                                                                                                                                                               
   16                                         214.6    96.1        ENO1          Alpha-enolase                                                                                                   517              1.74                     1.15
   18                                         212.7    99.7        ALDOA         Fructose-bisphosphate aldolase A                                                                                421              0.53                     1.19
   27                                         179.8    99.8        PGK1          Phosphoglycerate kinase 1                                                                                       296              0.47                     1.31
   43                                         124.9    100.0       ALDOC         Fructose-bisphosphate aldolase C                                                                                298              0.54                     1.20
   150                                        56.2     66.8        LDHB          [l]{.smallcaps}-Lactate dehydrogenase B chain                                                                   74               0.60                     1.16
   311                                        33.7     64.2        LDHA          [l]{.smallcaps}-Lactate dehydrogenase A chain                                                                   30               0.52                     1.29
  Pyruvate dehydrogenase complex                                                                                                                                                                                                           
   332                                        32.2     31.3        PDHA1         Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial                                  19               0.61                     1.19
   355                                        30.5     49.9        PDHB          Pyruvate dehydrogenase E1 component subunit beta, mitochondrial                                                 37               0.58                     1.21
   395                                        27.2     29.5        DLAT          Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial        20               0.34                     1.57
  Tricarboxylic acid cycle                                                                                                                                                                                                                 
   51                                         113.1    68.1        ACO2          Aconitate hydratase, mitochondrial                                                                              139              0.46                     1.38
   118                                        65.2     60.6        IDH2          Isocitrate dehydrogenase \[NADP\], mitochondrial                                                                39               0.35                     1.45
   222                                        42.8     63.9        FH            Fumarate hydratase, mitochondrial                                                                               40               0.44                     1.50
   253                                        39.1     56.6        IDH3A         Isocitrate dehydrogenase \[NAD\] subunit alpha, mitochondrial                                                   26               0.62                     1.19
   324                                        32.7     40.2        SUCLG1        Succinyl-CoA ligase \[ADP/GDP-forming\] subunit alpha, mitochondrial                                            35               0.49                     1.31
   565                                        20.0     31.5        SUCLA2        Succinyl-CoA ligase \[ADP-forming\] subunit beta, mitochondrial                                                 12               0.51                     1.26
  Oxidative phosphorylation                                                                                                                                                                                                                
   41                                         130.1    72.7        **ATP5A1**    ATP synthase subunit alpha, mitochondrial                                                                       124              0.57                     1.26
   42                                         129.9    80.5        ATP5B         ATP synthase subunit beta, mitochondrial                                                                        191              0.52                     1.20
   168                                        51.9     77.8        ATP5J         ATP synthase-coupling factor 6, mitochondrial                                                                   64               1.75                     1.19
   178                                        49.9     40.4        NDUFS1        NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial                                                    35               0.49                     1.36
   193                                        47.6     55.4        DLD           Dihydrolipoyl dehydrogenase, mitochondrial                                                                      29               0.53                     1.26
   202                                        45.6     61.6        **UQCRC2**    Cytochrome b--c1 complex subunit 2, mitochondrial                                                               36               0.53                     1.36
   274                                        37.7     78.9        ATP5O         ATP synthase subunit O, mitochondrial                                                                           29               0.51                     1.45
   340                                        31.8     45.7        **SDHB**      Succinate dehydrogenase \[ubiquinone\] iron--sulfur subunit, mitochondrial[b](#tf0015){ref-type="table-fn"}     22               0.72                     1.13
   1232                                       6.2      19.4        **MT-CO2**    Cytochrome c oxidase subunit 2[b](#tf0015){ref-type="table-fn"}                                                 4                1.06                     1.21
   1260                                       6.1      28.0        **NDUFB8**    NADH dehydrogenase \[ubiquinone\] 1 beta subcomplex subunit 8, mitochondrial[b](#tf0015){ref-type="table-fn"}   4                0.95                     1.15
  **Vascular dysfunction and inflammation**                                                                                                                                                                                                
   17                                         214.3    92.1        ALB           Serum albumin                                                                                                   235              2.03                     1.29
   30                                         161.4    100.0       HBB           Hemoglobin subunit beta                                                                                         356              0.26                     1.39
   126                                        62.3     31.3        L1CAM         Neural cell adhesion molecule L1                                                                                56               1.49                     1.12
   157                                        53.7     38.0        **NCAM1**     Neural cell adhesion molecule 1                                                                                 37               1.79                     1.32
   256                                        38.7     31.8        **ICAM5**     Intercellular adhesion molecule 5                                                                               31               1.75                     1.21
   265                                        38.1     27.8        FGA           Fibrinogen alpha chain                                                                                          25               2.23                     1.53
   326                                        32.5     57.8        IGHA1         Ig alpha-1 chain C region                                                                                       24               5.55                     2.36
   383                                        28.3     47.5        IGHG2         Ig gamma-2 chain C region                                                                                       20               4.02                     1.84
   419                                        26.0     96.6        HBD           Hemoglobin subunit delta                                                                                        152              0.54                     1.21
   442                                        25.2     26.8        IGSF8         Immunoglobulin superfamily member 8                                                                             15               2.13                     1.46
   461                                        24.2     47.9        FGB           Fibrinogen beta chain                                                                                           15               1.94                     1.46
   609                                        18.4     74.5        IGLC2         Ig lambda-2 chain C regions                                                                                     13               3.77                     1.96
   734                                        14.5     90.6        IGKC          Ig kappa chain C region                                                                                         20               4.41                     2.17
   1256                                       6.1      3.0         COL6A3        Collagen alpha-3(VI) chain                                                                                      8                1.79                     1.29
  **Synaptic transmission**                                                                                                                                                                                                                
   9                                          266.6    99.8        ENO2          Gamma-enolase                                                                                                   586              1.58                     1.14
   26                                         181.9    98.4        PEBP1         Phosphatidylethanolamine-binding protein 1                                                                      342              1.57                     1.17
   119                                        65.0     39.9        ATP1A3        Sodium/potassium-transporting ATPase subunit alpha-3                                                            45               2.96                     1.53
   121                                        63.7     80.1        RPS27A        Ubiquitin-40S ribosomal protein S27a                                                                            55               3.87                     1.74
   133                                        60.1     43.8        **SYNPO**     Synaptopodin[b](#tf0015){ref-type="table-fn"}                                                                   46               0.73                     1.10
   141                                        58.2     52.8        PPP3CA        Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform                                         52               0.57                     1.27
   218                                        43.3     49.2        ABAT          4-Aminobutyrate aminotransferase, mitochondrial                                                                 26               0.59                     1.21
   244                                        40.1     40.5        ALDH9A1       4-Trimethylaminobutyraldehyde dehydrogenase                                                                     29               0.56                     1.26
   345                                        31.6     65.0        SNAP25        Synaptosomal-associated protein 25                                                                              34               1.64                     1.20
   358                                        30.3     36.5        **STX1B**     Syntaxin-1B                                                                                                     23               1.89                     1.29
   463                                        24.1     14.3        SLC1A2        Excitatory amino acid transporter 2                                                                             22               2.63                     1.51
   667                                        16.5     29.5        **STX1A**     Syntaxin-1A                                                                                                     9                1.85                     1.26
   783                                        13.3     26.0        ATP1A2        Sodium/potassium-transporting ATPase subunit alpha-2                                                            32               2.21                     1.60
  **Oxidative stress**                                                                                                                                                                                                                     
   63                                         99.0     99.3        **SOD1**      Superoxide dismutase \[Cu--Zn\]                                                                                 188              3.02                     1.72
   134                                        59.8     82.5        **FTH1**      Ferritin heavy chain                                                                                            135              2.05                     1.41
   152                                        55.4     63.4        **FTL**       Ferritin light chain                                                                                            80               2.21                     1.41
   208                                        44.5     85.7        PRDX6         Peroxiredoxin-6                                                                                                 48               0.41                     1.45
   279                                        37.2     84.7        GPX1          Glutathione peroxidase 1[b](#tf0015){ref-type="table-fn"}                                                       30               1.18                     1.13
   898                                        11.0     14.2        GSR           Glutathione reductase, mitochondrial[b](#tf0015){ref-type="table-fn"}                                           8                0.63                     1.26
  **Chaperonic function**                                                                                                                                                                                                                  
   70                                         90.8     60.9        HSPA5         78 kDa glucose-regulated protein                                                                                94               1.42                     1.12
   72                                         88.6     61.1        HSP90AA1      Heat shock protein HSP 90-alpha                                                                                 79               0.43                     1.45
   92                                         76.2     67.2        STIP1         Stress-induced-phosphoprotein 1                                                                                 61               1.45                     1.15
   132                                        60.2     53.5        **HSPA4**     Heat shock 70 kDa protein 4                                                                                     40               0.46                     1.42
   255                                        38.7     96.1        HSPB1         Heat shock protein beta-1                                                                                       63               1.77                     1.17
   330                                        32.3     44.0        CCT8          T-complex protein 1 subunit theta                                                                               19               1.80                     1.29
   656                                        17.0     80.6        TBCA          Tubulin-specific chaperone A                                                                                    16               1.57                     1.20
  **Others**                                                                                                                                                                                                                               
   71                                         90.6     37.6        NFASC         Neurofascin                                                                                                     72               1.75                     1.26
   73                                         87.9     96.1        **VDAC1**     Voltage-dependent anion-selective channel protein 1                                                             91               0.56                     1.17
   84                                         80.6     100         SNCG          Gamma-synuclein[b](#tf0015){ref-type="table-fn"}                                                                91               1.08                     1.04
   200                                        46.0     33.4        NPEPPS        Puromycin-sensitive aminopeptidase                                                                              27               0.42                     1.47
   203                                        45.4     97.7        **PEA15**     Astrocytic phosphoprotein PEA-15                                                                                42               1.56                     1.15
   651                                        17.2     15.1        PREP          Prolyl endopeptidase                                                                                            10               0.58                     1.20
   799                                        12.8     37.4        PSMA6         Proteasome subunit alpha type-6                                                                                 8                0.64                     1.26

The gene symbols of the proteins selected for WB validation are shown in bold. The proteins have been classified based on their respective primary function/pathway. The energy metabolism category is sub-divided into four groups. Majority of the proteins related to energy metabolism were down-regulated, while proteins related to inflammation (immune response and cell adhesion) were up-regulated. Proteins participating in synaptic transmission and chaperonic function displayed a mixed trend.

The list of proteins qualified through the preset selection criteria (unused prot score \> 2.0, p \< 0.05, regulation cut-off : 1.4 fold compared to the control group) along with their relative quantitative values. The gene symbols of the proteins selected for WB validation are shown in bold. The proteins have been classified based on their respective primary function/pathway. The energy metabolism category is sub-divided into four groups. Majority of the proteins related to energy metabolism were down-regulated, while proteins related to inflammation (immune response and cell adhesion) were up-regulated. Proteins participating in synaptic transmission and chaperonic function displayed a mixed trend.

Proteins incorporated in the list due to their close association with the regulated proteins although they did not meet the above-mentioned preset selection criteria. For example, the fold of down-regulation was \< 1.4 fold for SYNPO, while others (e.g. SDHB, SNCG) doesn\'t have a significant *p*-value (i.e. *p* \> 0.05).

[^1]: Equal contribution.
